|
|
|
2010³â04¿ù18ÀÏ 00½Ã00ºÐ |
|
|
|
|
´ëÇѸ¶Ãë¾à¸®ÇÐȸ Çмú»ó ¼ö»óÀÚ
|
|
´ëÇѸ¶Ãë¾à¸®ÇÐȸ(ȸÀå µµ»óȯ, ºÐ´ç¼¿ï´ëº´¿ø ¸¶Ãë°ú)°¡ Áö³ 17ÀÏ ¹é¹ü±è±¸±â³ä°ü¿¡¼ Çмú´ëȸ ¹× ´ëÇѽŰæ±Ù¿¬±¸È¸ ½ÉÆ÷Áö¾öÀ» °³ÃÖÇß´Ù.
À̹ø Çмú´ëȸ¿¡¼ Á¤±âÃÑȸ¸¦ ÅëÇØ Çмú»óÀÌ ¼ö»óµÆ´Ù. ÁÖ¿ä ¼ö»óÀÚ´Â ´ÙÀ½°ú °°´Ù.
¡ßGSK Çмú»ó
¡ã°¡Å縯ÀÇ´ë ¸¶ÃëÅëÁõÀÇÇб³½Ç ±èÀº¼º ±³¼öÆÀ
ÁÖÁ¦ : ‘RemifentanilÀÌ º¹°°æÇÏ ÀÚ±ÃÀýÁ¦¼ú ȯÀÚ¿¡¼ Tumor necrosis factor-α¿Í Interleukin-6 ¹ÝÀÀ¿¡ ¹ÌÄ¡´Â ¿µÇâ
¡ã¼¿ï´ëÀÇ´ë ¸¶ÃëÅëÁõÀÇÇб³½Ç ¹Ú»óÇå ±³¼öÆÀ
ÁÖÁ¦ : Controlling deliberate hypotension in hypertensive patients undergoing spinal surgery: a comparison between remifentanil and sodium nitroprusside
¡ß¿ì¼öÇмú»ó
¡ã°Ç±¹´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ¸¶ÃëÅëÁõÀÇÇаú Á¤È¼º ±³¼öÆÀ
ÁÖÁ¦ : Remifentanil ¸ñÇ¥³óµµÁ¶ÀýÁÖÀԽà ¸ñÇ¥³óµµÀÇ Á¾·ù¿Í ¼³Á¤°ªÀÌ remifentanil ÁÖÀÔ¼Óµµ¿Í ÁÖÀÔ·®¿¡ ¹ÌÄ¡´Â ¿µÇâ : ½Ã¹Ä·¹ÀÌ¼Ç ¿¬±¸
¡ã´Ü±¹´ëÀÇ´ë ¸¶ÃëÅëÁõÀÇÇб³½Ç ±èµ¿Èñ ±³¼ö
ÁÖÁ¦ : Seventy-two hour peri-operative volume replacement with 6% HES 130/0.4 vs. 20% albumin in patients undergoing abdominal, cranial, and orthopedic surgery
¡ß¿ì¼öÃÊ·Ï»ó
¡ã¿ï»êÀÇ´ë ÀÓ»ó¾à¸®Çб³½Ç ÃÖÇѱ⠱³¼öÆÀ
ÁÖÁ¦ : Population PKPD modeling of microemulsion propofol
¡ã¼¿ï¾Æ»êº´¿ø ÀÓ»ó¾à¸®Çаú À̼öÇÑ ±³¼öÆÀ
ÁÖÁ¦ : Predictive performance of Aquafol TCI system
¡ãµ¿±¹´ëÀϻ꺴¿ø ¸¶ÃëÅëÁõÀÇÇб³½Ç ÀÌÀ±¼® ±³¼öÆÀ
ÁÖÁ¦ : Hyperventilation delays induction of desflurane
¡ãºÐ´ç¼¿ï´ëº´¿ø Á¶ÇöÁ¤ ±³¼öÆÀ
ÁÖÁ¦ : Intubating conditions by magnesium during rapid intubation
|
|
|
|
|
|